Thrombus - 2007

Calciphylaxis: rarely seen and poorly understood
Girish Purohit, Jonathan MR Goulding, Robert Charles-Holmes, Peter Rose, Paneesha Shankaranayana
pp 1-4
Calciphylaxis, also referred to as calcific uraemic arteriolopathy, is a rare calcification syndrome associated with cutaneous ischaemic necrosis. It is seen almost exclusively in patients with renal disease and secondary hyperparathyroidism but can, rarely, occur in their absence. Its incidence is rising. It is often diagnosed late, contributing to the very high mortality rate, ranging between 50%–80% of cases. Death in these patients is often attributed to associated wound infection, sepsis and organ failure.
Comment: Thromboprophylaxis for cancer patients
Peter Rose
pp 2-2
Risk stratification for medical and surgical hospital inpatient thromboprophylaxis is a major issue for all hospital patients following the recent Chief Medical Officer’s report and NICE guidance. Implementation of thromboprophylaxis remains a difficult problem, particularly for medical inpatients. To date there have been no prospective studies evaluating the clinical algorithms currently in use.
UK outpatient VTE outcomes
Denise O’Shaughnessy and Celestine O’Shaughnessy
pp 5-6
The total annual burden of venous thromboembolism (VTE) across the 27 member states of the European Union (population 459 million) is estimated to be 640,000 symptomatic deep vein thromboses and 383,000 pulmonary embolism (PE). VTE-related deaths are estimated at approximately 480,000. Of these deaths, 34,450 (7%) patients had been diagnosed with VTE and treated, 163,050 (34%) are estimated to be sudden fatal PE and 281,000 (59%) follow undetected PE.
Report from the 21st ISTH Congress
Tim Farren, Celestine O’Shaughnessy and Denise O’Shaughnessy
pp 7-8
The 21st Congress of the International Society on Thrombosis and Haemostasis (ISTH) took place from 6–12 July 2007 in Geneva, Switzerland.With around 7,800 delegates from all over the world, it was the largest attended to date. Here, we highlight some issues of interest.
The role of MRI in thrombosis diagnosis
Sharon Zahra
pp 9-11
Venous thromboembolism (VTE) is one of the commonest clinical problems, with an estimated incidence of three to four suspected cases per 1,000 general population every year. Of these, 0.1% and 0.05% are proven to have deep vein thrombosis (DVT) and pulmonary embolism (PE) respectively. Rapid, accurate diagnosis of VTE is essential. If it is untreated, VTE is associated with a fatal recurrence rate of 30% and a non-fatal second event in a further 30% of patients.

Thrombus was previously supported by Bayer from 2014 to 2016, by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2019 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)